Byotrol plc
BYOTROL plc -
HEALTHCARE PRODUCT LAUNCH
The Directors of Byotrol plc (the "Company") are pleased to be able to report
that the Company's strategic healthcare partner, Synergy Healthcare plc, has
announced the launch of a range of anti-microbial products containing Byotrol
technology.
The products have been developed for sale to the NHS primary and acute care
sectors and these will be marketed under the assure plus brand name.
A range of products for use in care homes will be marketed under the assure
brand name.
Byotrol Deputy Chairman Stephen Falder said, "We are delighted that our
healthcare partner has launched a comprehensive product range into the
marketplace and this coupled with the work we have undertaken to prove the
efficacy of the Byotrol technology will act as key drivers for sales in the
months ahead."
Enquiries:
-0-
*T
Byotrol plc
Stephen Falder
Deputy Chairman
David McRobbie
Chief Executive 0161 277 9518
Charles Stanley Securities
Philip Davies 020 7149 6457
McCann Erickson PR
Jim Rothnie 01625 822540
Rawlings Financial
John Rawlings 01756 770376
*T
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.